Perioperative Fluorouracil + Leucovorin, Oxaliplatin, and Docetaxel vs Fluorouracil or Capecitabine + Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or GE Junction Adenocarcinoma
A phase II/III trial investigated a chemotherapy triplet, FLOT (docetaxel, oxaliplatin, 5-FU/LV), as perioperative therapy in resectable gastroesophageal cancers compared with ECF/ECX,... Read More
Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
A new phase 3 trial of Bemarituzumab for patients with advanced gastric cancer is open for enrollment. Curious about clinical trials? Use... Read More
Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists
Scientists review the emerging trends in the use of antagonists to proteins PD-1/PD-L1 and gastrointestinal tumors.
BeiGene Initiates Global Phase 3 Trial of PARP Inhibitor Pamiparib in Patients with Advanced Gastric Cancer
A global Phase 3 trial is comparing the efficacy and safety of pamiparib to placebo as maintenance therapy in advanced gastric cancer... Read More
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
A new study published in The Lancet finds Keytruda, the PD-1 antibody pembrolizumab, may offer a better safety profile but does not... Read More
Checkpoint inhibitors for the treatment of metastatic gastric cancers
Researchers evaluate early-phase and late-phase trials of immunotherapy in advanced gastric cancer. Read the full article in Cancer Treatment Reviews, Evolution of checkpoint... Read More
Taiho Oncology Announces Positive Topline Results from Pivotal Phase 3 Trial of LONSURF® (trifluridine/tipiracil) in Metastatic Gastric Cancer
Here’s some positive news to kick off the weekend! A clinical trial of Lonsurf (trifluridine and tipiracil) plus supportive care improved overall... Read More
Added radiotherapy does not improve gastric cancer survival
New findings from an international clinical trial: postoperative chemoradiotherapy after gastric cancer surgery does not improve overall survival, compared with postoperative chemotherapy... Read More
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy
A new study in The Lancet, Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised... Read More
Immunotherapy on the Horizon in Gastric Cancer
While the utilization of immunotherapy in gastric cancer may not be as clear cut as it is in melanoma or lung cancer,... Read More